Clinical Study in the Treatment of Patients With COVID-19

Summary

Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study. The study is designed for 2 treatment groups: * Group 1 of the investigational drug - Patients receive standard therapy and the investigational drug. * Group 2 of comparison - Patients receive standard therapy and placebo.

Timeline

Start

2021-03-09

Primary completion

2022-05-31

Completion

2022-09-30

Drugs

Indications